Third-Party Platform Providers Shall Not be Directly Involved in Online Pharmaceutical Sales Activities

The National Medical Products Administration released the “People’s Republic of China Drug Administration Law Implementation Regulations (revised draft for comment)”, which proposed that “third-party platform providers shall not be directly involved in online pharmaceutical sales activities”. Right after this news, pharmaceutical retail stocks went up considerably, but internet healthcare stocks noticeably went down. If this proposal is actually implemented, people suspect that e-commerce platforms such as Ali Health and JingDong Health will be impacted negatively when forced to choose between third-party platform services and self-operating businesses. (Source: shuzhengkangxun)

Visit HPA-China’s Information Hub, CLICK HERE